YPrime: ‘The future is about applying standards’

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/kentoh)
(Image: Getty/kentoh)

Related tags: eclinical, Data standards, YPrime

Sponsors committed to standardizing data can benefit from ‘more than improved efficiency,’ says YPrime VP, as the company expands its eClinical portfolio to include data standards, clinical analytics and eCOA consulting services.

As part of the expansion, the company has named Terek Peterson as the vice president of clinical analytics and data strategies.

“We want to build awareness about the importance of standards and about the opportunities our customers have to apply them to their advantage,”​ said Peterson, who will lead the team focused on CDISC data collection and submission standards.

“Any time you need data to make a decision, you have an advantage if data are standardized and analysis-ready,”​ added Peterson. “Sponsors who commit to standardizing data and invest in early planning can benefit from more than improved efficiency.”

As Peterson told us, standardization also can increase the value of clinical trial libraries, by using retrospective data in metadata analyses and new submissions.

Where it previously took years to get studies ‘in shape’ for CDISC-compliant submissions, Peterson said, now, “these data can be sitting on a shelf, ready to go.”

“The future is about applying standards to YPrime systems so that transfers are automatic, and data are in standard format on demand,”​ he added.

“When we can build eCOA platforms with standardized data automatically pulled into the study build, we will be able to deliver greater visibility while studies are ongoing. Next, we could connect to wearable sensors and other devices,”​ said Peterson.

“If sponsors are not preparing for this future now, they won’t be able to take advantage of emerging technologies coming down the road that offer transformative benefits to time, cost and data quality,”​ he added.

Speaking to its eCOA consulting services, Mark Maietta, president of YPrime, said the company helps customers in various areas.  

“Experienced eCOA managers often require consultation on design, planning, and process to ensure implementation consistent with industry best practices and regulatory expectations,”​ he told us.

Related news

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more